These inhibitors further perturb oncogenic K-Ras PM nanoclustering and its signaling, and abrogate the growth of different types of human cancer cells expressing oncogenic mutant K-Ras but not WT K-Ras (Petersen et al., 2013; van der Hoeven et al., 2013; van der Hoeven et al., 2018). Here, KRAS is linked to cancer.